Notice Number: NOT-HL-19-742
Key Dates
Release Date: January 15, 2020
PAR-19-343
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PAR-19-343, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)."
The following sections of PAR-19-343 have been updated to reflect the participation of NHLBI in this Funding Opportunity Announcement (FOA). Additions are italicized.
Part 1. Overview Information
Components of Participating Organizations
National Institute of General Medical Sciences (NIGMS)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Nursing Research (NINR)
National Institute on Minority Health and Health Disparities (NIMHD)
National Human Genome Research Institute (NHGRI)
National Institute on Aging (NIA)
National Heart, Lung and Blood Institute (NHLBI)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.859, 93.286, 93.361, 93.307, 93.172, 93.866, 93.233, 93.837, 93.838, 93.839, 93.840
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Program Considerations
The MOSAIC K99/R00 program is intended to foster the development of creative, innovative, independent researchers who will be competitive for subsequent independent biomedical research funding, and who will enhance diversity in the biomedical research workforce.
The specific NIH Institute and Center scientific areas supported through this FOA include the following:
NIGMS supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS' research mission is aimed at understanding the principles, mechanisms, and processes that underlie living systems. It also supports research in specific clinical areas that affect multiple organs, particularly those related to injury and critical illness: sepsis, trauma, burn, wound healing, anesthesiology, and clinical pharmacology. For more information see https://www.nigms.nih.gov/about/overview/pages/default.aspx.
NHLBI provides global leadership for a research, research training, and education program to promote the prevention and treatment of heart, lung, blood, and sleep diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The NHLBI encourages research designed to answer the breadth of scientific questions related to heart, lung, blood, and/or sleep diseases, disorders, and phenotypes. The NHLBI seeks applications that will address questions relevant to the NHLBI mission, address gaps in the NHLBI's portfolio, and should align with the NHLBI's Strategic Vision. NHLBI's strategic priorities emphasize the continuum of research from basic molecular biology research to implementation science related to heart, lung, blood diseases and sleep disorders (e.g., hemoglobinopathies and other non-malignant blood diseases; thrombotic and hemostasis disorders; cardiovascular diseases; hypertension prevention and control; asthma; chronic obstructive pulmonary disease (COPD), sleep apnea; and other cardiopulmonary diseases and conditions), self-management of symptoms and disease conditions, and prevention of these diseases and disorders in various populations. The NHLBI also has significant interests in implementation science research for the prevention, control, and treatment of heart, lung, blood diseases and sleep disorders, particularly research that addresses the development of interventions or strategies that address the translation of proven effective evidence-based interventions into clinical, community, and/or other real world settings; addresses impediments to uptake, scale up, and sustainability of evidence-based interventions in various contexts; examines disparities in disease burden and ways to mitigate these disparities; and/or models possible treatment paradigms. Please refer to the NHLBI website for more details on the research priorities of the NHLBI.
All other aspects of this FOA remain the same.
Inquiries
Please direct all inquiries to:
Scientific/Research Contact(s)
Nicole Redmond, M.D., Ph.D., M.P.H.
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0379
Email: [email protected]
Sharon M. Smith, Ph.D.
Division of Blood Diseases and Disorders
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: [email protected]
Xenia Tigno, Ph.D.
Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0202
Email: [email protected]
Melissa Green Parker, Ph.D.
Center for Translation Research and Implementation Science
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-496-1051
Email: [email protected]
Peer Review Contact(s)
Director, Office of Scientific Review
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0270
Email: [email protected]
Financial/Grants Management Contact(s)
Benjamin Sakovich
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0166
Email: [email protected]
and Human Services (HHS)
